These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2940997)

  • 1. [Multicenter study with 3 different doses of ketanserin in essential arterial hypertension].
    Cruz J; Moscovici H; Silva AN; Finkielman S; Milei J; Geyer G; Feltkamp H; Stumpe KO; Berges LC
    Arq Bras Cardiol; 1985 Oct; 45(4):299-304. PubMed ID: 2940997
    [No Abstract]   [Full Text] [Related]  

  • 2. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
    Podoleanu D; Cotoi S
    Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
    Cameron HA; Ramsay LE
    Postgrad Med J; 1985 Jul; 61(717):583-6. PubMed ID: 3161013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
    De Lorenzo A; Ceccanti M; Romeo M; Pisculli M; Di Giovanni MG; Lais A; Assogna G; Valgiusti FC
    Int J Clin Pharmacol Res; 1986; 6(1):77-9. PubMed ID: 2937747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diazoxide in arterial hypertensive emergencies].
    Bedani PL; Farinelli A
    Clin Ter; 1979 May; 89(3):267-81. PubMed ID: 380880
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical experience report on the combination antihypertensive agents DCR 1015 and DCR 515].
    Obrowsky L; Kern H
    Wien Med Wochenschr; 1969 Jan; 119(2):36-9. PubMed ID: 4976539
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effectiveness of captopril (tensiomin) in the long-term treatment of arterial hypertension].
    Kakaliia E; Belousov IuB; Bykov AV; Sidorskiĭ AL
    Sov Med; 1991; (10):45-8. PubMed ID: 1801235
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular effects of ketanserin in the treatment of hypertension during coronary artery bypass surgery.
    Richter JA; Barankay A; Göb E; Späth P
    J Cardiovasc Pharmacol; 1986; 8(1):109-15. PubMed ID: 2419672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-effect relationships and antihypertensive mechanisms: ketanserin in the treatment of essential hypertension.
    Elliott HL; Meredith PA
    J Hypertens Suppl; 1990 Sep; 8(4):S69-71. PubMed ID: 2258787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic effects of an antihypertensive diuretic substance on the forearm circulation of patients with essential hypertension.
    Bouthier JA; Safar ME; Deschamps E; Tarrade T
    Drugs Exp Clin Res; 1988; 14(2-3):221-4. PubMed ID: 3416724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prolonged treatment with ketanserin in essential hypertension and comparison with metoprolol].
    Finkielman S
    Medicina (B Aires); 1985; 45(4):447-9. PubMed ID: 3916016
    [No Abstract]   [Full Text] [Related]  

  • 16. [Minimal useful dose of guanfacine in patients with essential hypertension].
    Pérez Olea J; Ortíz N; Soledad Bertoló M; Allel L; Goity C; Quevedo M
    Rev Med Chil; 1985 May; 113(5):420-4. PubMed ID: 3912882
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 18. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of preeclamptic hypertension by ketanserin, a new serotonin receptor antagonist.
    Weiner CP; Socol ML; Vaisrub N
    Am J Obstet Gynecol; 1984 Jul; 149(5):496-500. PubMed ID: 6377898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of combination therapy in treatment of hypertension].
    Kreutz R
    Krankenpfl J; 2005; 43(7-10):255. PubMed ID: 16515324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.